Tagami Tatsuaki, Ozeki Tetsuya
Drug Delivery and Nano Pharmaceutics, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya, Aichi 467-8603, Japan.
Drug Delivery and Nano Pharmaceutics, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya, Aichi 467-8603, Japan.
J Pharm Sci. 2017 Sep;106(9):2219-2226. doi: 10.1016/j.xphs.2017.02.026. Epub 2017 Mar 1.
Clinical trials related to carrier-based drugs have recently attracted attention because carrier-based drugs hold promise for high efficiency drug delivery and for reducing drug-related side effects. In this commentary, we introduce recent clinical trials involving the use of various carriers, including liposomes, nano and micro particles, micelles, emulsions, and polymeric carriers. Liposomal drug carriers are currently the most intensively tested carriers in clinical trials, but other carriers such as polymeric carriers, albumin-based carriers, and metal nanocarriers have also recently been studied in clinical trials. Each carrier has specific properties, advantages, and disadvantages. The recent clinical trials introduced herein provide information critical to understanding current trends in carrier-based drug research.
基于载体的药物相关临床试验最近备受关注,因为基于载体的药物有望实现高效给药并减少药物相关副作用。在本评论中,我们介绍了近期涉及使用各种载体的临床试验,包括脂质体、纳米和微粒、胶束、乳剂以及聚合物载体。脂质体药物载体是目前临床试验中测试最为密集的载体,但其他载体,如聚合物载体、白蛋白基载体和金属纳米载体,最近也在临床试验中得到了研究。每种载体都有其特定的性质、优点和缺点。本文介绍的近期临床试验提供了对于理解基于载体的药物研究当前趋势至关重要的信息。